Allegheny Health Network
Find a
Doctor
Request An Appointment Login to
MyChart
Patient
Center
News Classes &
Events
Contact
Us
Call 412.Doctors

Active Clinical Trials

CHECKMATE 816

Active NCT:
02998528
Allegheny General Hospital
Allegheny General Hospital

Allegheny Valley Hospital
Allegheny Valley Hospital

Forbes Hospital
Forbes Hospital

Jefferson Hospital
Jefferson Hospital

West Penn Hospital
West Penn Hospital

Wexford Health + Wellness Pavilion
Wexford Health + Wellness Pavilion

Category:
Cancer - Lung
Sponsor: 
Bristol Myers Squibb
Contact: 

For more information, please contact Mara Yerk at 412-578-5393 or Mara.Yerk@ahn.org

CA209816: Randomized, Open Label, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum Doublet Chemotherapy in Early Stage NSCLC (Checkmate 816)

Purpose: 

The purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab compared to chemotherapy in the treatment of Early Stage Non-Small Cell Lung Cancer.

Ages Eligible for Study: 18 Years and older (Adult, Senior)
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue
  • Lung function capacity capable of tolerating the proposed lung surgery
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  • Available tissue of primary lung tumor

Exclusion Criteria:

  • Presence of locally advanced, inoperable or metastatic disease
  • Participants with active, known or suspected autoimmune disease
  • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)
  • Other protocol defined inclusion/exclusion criteria could apply